for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalyst Pharmaceuticals Inc

CPRX.O

Latest Trade

4.31USD

Change

0.00(-0.00%)

Volume

1,750,934

Today's Range

4.29

 - 

4.45

52 Week Range

2.55

 - 

7.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.31
Open
4.45
Volume
1,750,934
3M AVG Volume
44.39
Today's High
4.45
Today's Low
4.29
52 Week High
7.67
52 Week Low
2.55
Shares Out (MIL)
103.42
Market Cap (MIL)
458.13
Forward P/E
11.81
Dividend (Yield %)
--

Next Event

Catalyst Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Catalyst Pharma Sees FY 2020 Revenue $135 Mln To $155 Mln

Catalyst Pharmaceuticals Reports Q4 GAAP Earnings Per Share $0.07

Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse Revenues

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry

Biotechnology & Drugs

Contact Info

355 Alhambra Cir Ste 1250

CORAL GABLES, FL

33134-5038

United States

+1.305.5292522

https://catalystpharma.com/

Executive Leadership

Patrick James McEnany

Chairman of the Board, President, Chief Executive Officer

Alicia Grande

Chief Financial Officer, Vice President, Treasurer

Steven R. Miller

Chief Operating Officer, Chief Scientific Officer

Brian D. Elsbernd

Chief Compliance Officer, Chief Legal Officer

Daniel J. Brennan

Chief Commercial Officer

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.210

2018

-0.330

2019

0.300

2020(E)

0.375
Price To Earnings (TTM)
10.99
Price To Sales (TTM)
3.85
Price To Book (MRQ)
4.60
Price To Cash Flow (TTM)
10.65
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
56.40
Return on Equity (TTM)
48.00

Latest News

Latest News

BRIEF-Catalyst Pharma Sees FY 2020 Revenue $135 Mln To $155 Mln

* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG

BRIEF-Catalyst Pharmaceuticals CEO, On Impact Of Covid-19, Says Implementing Virtual Approach To Guarantee Patients Continual Access To Firdapse

* CATALYST PHARMACEUTICALS CEO, ON IMPACT OF COVID-19, SAYS IMPLEMENTING VIRTUAL APPROACH TO GUARANTEE PATIENTS CONTINUAL ACCESS TO FIRDAPSE

BRIEF-Catalyst Pharmaceuticals Reports Q4 GAAP Earnings Per Share $0.07

* CATALYST PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Catalyst Pharma sues FDA over approval of cheaper rival drug

Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.

U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Catalyst defends drug price after Bernie Sanders' rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

Catalyst Pharma sees net price of drug, once free, topping $300,000

Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

BRIEF-Catalyst Pharma Submits NDA For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME

BRIEF-Catalyst Pharmaceuticals Announces Q4 Gaap Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage:

BRIEF-Catalyst Pharmaceuticals Inc Prices Previously Announced Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. PRICES PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Announces Proposed Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up